Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Amazighon Sep 09, 2021 7:58pm
110 Views
Post# 33838031

RE:Fellow Investors !!!

RE:Fellow Investors !!!
HighSkies2019 wrote: 14 Million is we kept it and run thru phase 3 ourselves ....it could be sold as part of a combined deal ...maybe get enough to pay off Talent possibly a bit more to put in our pockets .. better then nothing and anything is possible .. what if Talent rejected the return and now we have the debt of 4 mil to pay ..while it rots on the shelf or will we have to pay more to Talent ...how much was offered b4 that Rob felt was not enough.. there were a few interested parties according to Bob in Aug 30 MD&A ....as for people getting kicked off the other sites .. I didn't really care and said it was your sites to run the way you want ...


Actually, that’s far from the truth. You said and I quote:

on their boards they kick investors out that don't agree with them

On the link I posted, you could clearly see proof that this was not the case.

but like you say facts are for cockroaches ...

You’re stretching the truth here again.
I said that “facts are like sunlight to cockroaches”, when you said that using fact and logic to counter those who are “expressing their thoughts or concerns in a post” and don’t use facts is “mocking” them and being “smug”.

A perfect example of not telling the truth is Sacloco’s misleading post where he thought or tries to convince us, we had conducted Phase III in GVHD and were Fast Tracked by the FDA and of course, Losinghisshirt promoting this misinformation as legitimate with ” SACLOCO SHINES THE LIGHT FOR NEW INVESTORS.”

When you stated that "and the only facts I am concerned with is what comes directly from the company.. "

Well, here are some facts from the company:

*We didn’t apply for Fast Track of GVHD program.

*We didn’t start Phase III for GVHD.

*We owed Talent $4 million dollars. We did not have $4 million dollars, so, we made an agreement to give them the GVHD program instead and cancel the debt we had with them.

*We never started Phase III for GVHD because we couldn’t get financing of $7 million.

In light of the financial impossibilities we had and not giving the GVHD back, but instead, paying the debt with money we did not have and then finding $10 million we could not have found to develop it ourselves, why on earth would you say “we still have potential chance to get a return on our GVHD” ?

What imaginary facts are behind that statement?
Why would you or any investor want that massive millstone around our neck that only provides a fractional return for higher output in development?

Facts only please, as you stated in your posts. You can use the official Claritas site and the MD&A’s as your source: you know, the ones that say we couldn't sell it, rent it, and, it would cost well over $14 million to proceed with the GVHD program.


<< Previous
Bullboard Posts
Next >>